Kidney and haemostasis

2015 ◽  
Vol 35 (01) ◽  
pp. 73-76
Author(s):  
K. Andrassy

SummaryRenal insufficiency is characterized by thrombocytopathy, caused by the accumulation of water soluble and protein bound waste products of protein metabolism, which are not adequately eliminated by the kidney. The kidneys also excrete drugs and their metabolites, which accumulate if dosages are not adjusted to the renal function and may cause clinically relevant bleeding (i. e. synthetic penicillins, vitamin K antagonists, new oral anticoagulants). Therefore, each patients kidney function (GFR) ought to be evaluated by the KDIGO guidelines. The survival of chronic renal patients is lowered by increasing cardiovascular complications. Particularly frequent is non-valvular atrial fibrillation. The recommended prophylaxis with vitamin K antagonists for renal insufficiency is hampered by increased bleeding as well as by augmented (coronary) vascular and valvular calcification. It is not known yet whether prophylaxis with vitamin K may prevent this complication. Conclusion: Because new oral anticoagulants are equally or even more effective and cause less bleeding, they may be favoured in future and even in end-stage renal failure if more is known about dosing, safety and efficacy. The measurement of serum FGF 23 concentration may be helpful as a marker for their use.

2020 ◽  
pp. 55-61
Author(s):  
Natalya Yu. Timofeeva ◽  
Natalya A. Buryachenko ◽  
Irina S. Stomenskaya ◽  
Olga Yu. Kostrova ◽  
Gleb Yu. Struchko

The spread of cardiovascular pathology has brought its directives in the treatment of diseases. Currently, drugs from the groups of antiaggregants and new oral anticoagulants are widely used. Drugs belonging to the group of vitamin K antagonists do not lose their importance in the treatment of cardiological patients. Monitoring the treatment of these patients requires improvement of modern diagnostic technologies. A conventional coagulogram has now been replaced by a more modern method of diagnosing hemostasis disorders – thromboelastometry (TEM). TEM, unlike a standard coagulogram, enables to evaluate all the links of hemostasis in a limited period of time. This article presents a clinical case of poisoning with a drug from the anticoagulants group – warfarin and an example of using thromboelastometry in the diagnosis of this coagulopathy.


2010 ◽  
Vol 103 (01) ◽  
pp. 62-70 ◽  
Author(s):  
Jeffrey Weitz

SummaryAlthough currently available anticoagulants are effective for the prevention and treatment of thromboembolic disorders, they have several drawbacks. Low-molecular-weight heparins and fondaparinux produce a predictable level of anticoagulation that obviates the need for coagulation monitoring, but they must be given parenterally, which renders them inconvenient for long-term use. Vitamin K antagonists, such as warfarin, are administered orally, but produce a variable anticoagulant response because genetic polymorphisms, dietary vitamin K intake and multiple drug-drug interactions affect their metabolism. Consequently, coagulation monitoring and frequent dose adjustments are needed to ensure that a therapeutic level of anticoagulation is achieved. This is burdensome for patients and physicians, and costly for the healthcare system. These limitations have prompted the development of new oral anticoagulants that target thrombin or factor Xa and can be given in fixed doses without coagulation monitoring. This paper focuses on the new oral anticoagulants in the most advanced stages of development.


2018 ◽  
Vol 13 (3) ◽  
pp. 273
Author(s):  
Maodi Xu ◽  
Qingquan Xue ◽  
Zhichen Pu ◽  
Zijing Wu ◽  
Haitang Xie

<p>The aim of this meta-analysis was to systematically evaluate the efficacy and safety of novel oral anticoagulants and vitamin K antagonists in the treatment of venous thromboembolism. A total of 6 studies met the inclusion criteria and a total of 19,350 patients with venous thromboembolism were included. Among them, rivaroxaban (3 RCTs, n=90/3,449/4,832); dabigatran (2 RCTs, n=200/2,539); edoxaban (1 RCT, n=8,240). The results of meta-analysis showed that the total bleeding rate after treatment with the vitamin K antagonist group was higher than with the new oral anticoagulant group (OR=0.82, 95% confidence interval 0.75-0.90, p&lt;0.0001), and the difference was highly statistically significant. Overall, new oral anticoagulants are compara-ble to vitamin K antagonists, but new oral anticoagulants can reduce the occurrence of bleeding events and the safety was superior to vitamin K antagonists.</p>


2014 ◽  
Vol 11 (7) ◽  
pp. 680-684 ◽  
Author(s):  
Josep M. Alegret ◽  
Xavier Viñolas ◽  
Miguel A. Arias ◽  
Antoni Martínez-Rubio ◽  
Pablo Rebollo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document